HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer

Breast Cancer Research and Treatment

Volumn 108, Issue 2, 2008, Pages 183-190

  Andre, Fabrice ^a,b   Mazouni, Chafika ^b   Liedtke, Cornelia ^b   Kau, Shu Wan ^b   Frye, Debby ^b   Green, Marjorie ^b   Gonzalez Angulo, Ana M ^b   Symmans, W Fraser ^b   Hortobagyi, Gabriel N ^b   Pusztai, Lajos ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracycline; Breast neoplasms; Chemotherapy; Estrogen receptor; HER2; Paclitaxel; Predictive biomarker; Tau; Topoisomerase 2

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; TAU PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG EFFICACY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PATIENT SELECTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RNA, MESSENGER; TAU PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 39749153355     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9594-8     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. International Breast Cancer Study Group (2002) Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94:1054-1065
3. Albain K, Barlow W, O'Malley F et al (2004) Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium, Abst 37
4. Pritchard KI, Shepherd LE, O'Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111
5. Hayes DF, Thor A, Dressler L et al (2006) HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 24:18S Abs 510
6. Rouzier R, Pusztai L, Delaloge S et al (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-8339
7. Von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
8. Colleoni M, Viale G, Zahrieh D et al (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622-6628
9. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y et al (2004) Lack of association between amplification of HER2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101:258-263
10. Schneeweiss A, Katretchko J, Sinn HP et al (2004) Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs 15:127-135
11. Learn PA, Yeh IT, McNutt M et al (2005) HER2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103:2252-2260
12. Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211
13. Penault-Llorca F, Cayre A, Bouchet Mishellany F et al (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319-1325
14. Zhang F, Yang Y, Smith T et al (2003) Correlation between HER2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758-1765
15. Di Leo A, Isola J. (2003) Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 4:179-186
16. Rouzier R, Rajan R, Wagner P et al. (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320
17. Hess KR, Anderson K, Symmans W et al (2006) Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 24:4236-4244
18. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679
19. Yu D, Hung MC (2000) Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680
20. Hicks DG, Yoder BJ, Pettay J et al (2005) The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36:348-356
21. MacGrogan G, Rudolph P, Mascarel I et al (2003) DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer. Br J Cancer 89:666-671
22. Park K, Kim J, Lim S et al (2003) Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631-634